Pharmacologically targeting FATP2 diminished the evasive effect of MDSCs and tumor growth by reducing reactive oxygen species (ROS) and PD-L1 expression on tumor-infiltrating CD8+ T-cells (114, 115). The gene discussed is SLC27A2; the disease is neoplasm.